drugset / Trial / NCT05849922

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

NCT05849922

Phase 2 Completed 86 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

Timeline

Start
2023-06-06
Primary completion
2024-08-22
Completion
2025-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivekimig Protein / enzyme biologic 150 mg/ml